Press releases

These press releases are intended for business journalists and analysts/investors

Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab)

GSK Australia today announced that a new pre-filled pen (autoinjector) for the self-administration of its targeted therapy for severe eosinophilic asthma patients, NUCALA (mepolizumab), will be reimbursed by the Pharmaceutical Benefits Scheme (PBS) from 1 June 2020.

Read more - Greater flexibility for Australians with severe asthma with reimbursement of at-home, self-administration delivery of NUCALA® (mepolizumab) Read more

GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC

GlaxoSmithKline (GSK) Australia has reported its 2019 results to the Australian Securities and Investment Commission (ASIC) for its pharmaceuticals and vaccines business, and ViiV Healthcare Australia (a joint venture with Pfizer and Shionogi focused on HIV). GSK Australia’s Consumer Healthcare business will report separately in the coming months.

Read more - GSK Australia reports 2019 results (excluding Consumer Healthcare) to ASIC Read more

GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer

GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer, following an agreement reached with Takeda Australia. This transfer of marketing authorisation is an important first step in the process for GSK to make this medicine available to Australian patients.

Read more - GSK Australia now holds the marketing authorisation for Zejula (niraparib) for ovarian cancer Read more

Important update for health care professionals re: expiry date of Priorix, our measles, mumps and rubella vaccine

GlaxoSmithKline Australia (GSK), in consultation with the Therapeutic Goods Administration, would like to provide the following information to ensure that there is no confusion in relation to the expiration date of measles, mumps and rubella vaccine (MMR), Priorix.

Read more - Important update for health care professionals re: expiry date of Priorix, our measles, mumps and rubella vaccine Read more